APA (7th ed.) Citation

J, B., I, B., C, S., G, B., J, E., S, F., . . . R, F. (2019). Narciclasine inhibits angiogenic processes by activation of Rho kinase and by downregulation of the VEGF receptor 2. Journal of molecular and cellular cardiology, 135, 97. https://doi.org/10.1016/j.yjmcc.2019.08.001

Chicago Style (17th ed.) Citation

J, Bräutigam, Bischoff I, Schürmann C, Buchmann G, Epah J, Fuchs S, Heiss E, Brandes RP, and Fürst R. "Narciclasine Inhibits Angiogenic Processes by Activation of Rho Kinase and by Downregulation of the VEGF Receptor 2." Journal of Molecular and Cellular Cardiology 135 (2019): 97. https://doi.org/10.1016/j.yjmcc.2019.08.001.

MLA (9th ed.) Citation

J, Bräutigam, et al. "Narciclasine Inhibits Angiogenic Processes by Activation of Rho Kinase and by Downregulation of the VEGF Receptor 2." Journal of Molecular and Cellular Cardiology, vol. 135, 2019, p. 97, https://doi.org/10.1016/j.yjmcc.2019.08.001.